Stay updated with breaking news from Nasdaq Drrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DURECT (NASDAQ:DRRX – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday. Other analysts also recently issued reports about the stock. HC Wainwright downgraded shares of DURECT from a “buy” rating to a “neutral” rating in a research report on […]
Black Diamond Financial LLC bought a new stake in DURECT Co. (NASDAQ:DRRX – Free Report) in the third quarter, HoldingsChannel reports. The institutional investor bought 21,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $52,000. Several other institutional investors also recently made changes to their positions in the stock. Tower Research Capital LLC […]
DURECT Co. (NASDAQ:DRRX – Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,150,000 shares, a decline of 22.9% from the November 30th total of 2,790,000 shares. Approximately 7.3% of the company’s stock are sold short. Based […]
StockNews.com downgraded shares of DURECT (NASDAQ:DRRX – Free Report) from a hold rating to a sell rating in a report issued on Thursday morning. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reduced their price objective on shares of DURECT from $44.00 to $41.00 and set an overweight rating on […]
StockNews.com upgraded shares of DURECT (NASDAQ:DRRX – Free Report) from a sell rating to a hold rating in a research report report published on Wednesday. A number of other equities research analysts have also commented on DRRX. Cantor Fitzgerald decreased their price objective on DURECT from $44.00 to $41.00 and set an overweight rating for […]